Roche recasts itself as a Big Biotech

Think Roche is a Big Pharma company? Think again. From now on, Roche--which just completed a buyout of Genentech--is a Big Biotech company. And to help signal the switch Roche is dropping out of PhRMA and is taking up Genentech's top position in BIO. "Genentech and Roche believe BIO's purpose is closely aligned with the direction of the new company and, therefore, can represent the company's interest in Washington,'' spokeswoman Darian Wilson said. The switch came despite an 11th-hour appeal by PhRMA, which sent AstraZeneca CEO David Brennan to discuss the matter directly with Roche CEO Severin Schwann. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.